Skip to main content

Advertisement

SpringerLink
Log in

Neurohormonal modulation in heart failure of ischemic etiology: Correlates with left ventricular remodeling

  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

The natural progression of heart failure (HF) is accompanied by the compensatory activation of cardiac and extracardiac neurohormonal systems and changes in the anatomy and function of the left ventricle. The processes of ventricular remodeling and neurohormonal activation are mutually influenced so that strong associations may be observed between circulating concentrations of biomarkers (especially the natriuretic peptides originating from the heart) and parameters of left ventricle size and function. Temporal changes in the concentration of natriuretic peptides convey incremental prognostic value compared with a single determination and are usually related to concomitant changes in markers of left ventricle remodeling in patients with chronic HF. Whether knowledge of biomarkers’ concentration can improve the clinical outcome of patients with HF by helping in guiding and monitoring their therapy treatment is a stimulating working hypothesis still to be verified.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Cohn JN, Levine TB, Francis GS, Goldsmith S: Neurohumoral control mechanisms in congestive heart failure. Am Heart J 1981, 102:509–514.

    Article  PubMed  CAS  Google Scholar 

  2. Packer M: The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992, 20:248–254.

    Article  PubMed  CAS  Google Scholar 

  3. Cohn JN, Johnson G, Ziesche S, et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303–310.

    Article  PubMed  CAS  Google Scholar 

  4. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293–302.

    Article  Google Scholar 

  5. Waagstein F, Bristow MR, Swedberg K, et al.: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993, 342:1441–1446.

    Article  PubMed  CAS  Google Scholar 

  6. Australia/New Zealand Heart Failure Research Collaborative Group: Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997, 349:375–380.

    Article  Google Scholar 

  7. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERITHF). Lancet 1999, 353:2001–2007.

    Article  Google Scholar 

  8. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.

    Article  PubMed  CAS  Google Scholar 

  9. Pfeffer MA, Swedberg K, Granger CB, et al.: CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759–766.

    Article  PubMed  CAS  Google Scholar 

  10. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717.

    Article  PubMed  CAS  Google Scholar 

  11. Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000, 35:569–582.

    Article  PubMed  CAS  Google Scholar 

  12. Vasan RS: Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335–2362. A comprehensive review of the definition, characteristics, and evaluation of currently available and future biomarkers in cardiovascular diseases.

    Article  PubMed  Google Scholar 

  13. Anand IS, Florea VG, Fisher L: Surrogate end points in heart failure. J Am Coll Cardiol 2002, 39:1414–1421.

    Article  PubMed  Google Scholar 

  14. Konstam MA: Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol 2005, 96:867–871.

    Article  PubMed  Google Scholar 

  15. Follath F, Cleland JG, Klein W, Murphy R: Etiology and response to drug treatment in heart failure. J Am Coll Cardiol 1998, 32:1167–1172.

    Article  PubMed  CAS  Google Scholar 

  16. Levine TB, Francis GS, Goldsmith SR, et al.: Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982, 49:1659–1666.

    Article  PubMed  CAS  Google Scholar 

  17. Swedberg K, Viquerat C, Rouleau JL, et al.: Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol 1984, 54:783–786.

    Article  PubMed  CAS  Google Scholar 

  18. Goldsmith SR, Francis GS, Cowley AW Jr, et al.: Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983, 1:1385–1390.

    Article  PubMed  CAS  Google Scholar 

  19. McMurray JJ, Ray SG, Abdullah I, et al.: Plasma endothelin in chronic heart failure. Circulation 1992, 85:1374–1379.

    PubMed  CAS  Google Scholar 

  20. Jougasaki M, Wei CM, McKinley LJ, Burnett JC Jr: Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 1995, 92:286–289.

    PubMed  CAS  Google Scholar 

  21. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H: A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981, 28:89–94.

    Article  PubMed  Google Scholar 

  22. Sudoh T, Kangawa K, Minamino N, Matsuo H: A new natriuretic peptide in porcine brain. Nature 1988, 332:78–81.

    Article  PubMed  CAS  Google Scholar 

  23. Shenker Y, Sider RS, Ostafin EA, Grekin RJ: Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema. J Clin Invest 1985, 76:1684–1687.

    Article  PubMed  CAS  Google Scholar 

  24. Mukoyama M, Nakao K, Hosoda K, et al.: Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991, 87:1402–1412.

    PubMed  CAS  Google Scholar 

  25. Swedberg K, Cleland J, Dargie H, et al.: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005, 26:1115–1140.

    Article  PubMed  CAS  Google Scholar 

  26. Munger MA, Johnson B, Amber IJ, et al.: Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996, 77:723–727.

    Article  PubMed  CAS  Google Scholar 

  27. De Feo S, Franceschini L, Brighetti G, et al.: Ischemic etiology of heart failure identifies patients with more severely impaired exercise capacity. Int J Cardiol 2005, 104:292–297.

    Article  Google Scholar 

  28. Namiki A, Kubota T, Fukazawa M, et al.: Endothelin-1 concentrations in pericardial fluid are more elevated in patients with ischemic heart disease than in patients with nonischemic heart disease. Jpn Heart J 2003, 44:633–644.

    Article  PubMed  CAS  Google Scholar 

  29. Latini R, Masson S, Anand I, et al.: The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004, 25:292–299.

    Article  PubMed  CAS  Google Scholar 

  30. Hartmann F, Packer M, Coats AJ, et al.: Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004, 110:1780–1786.

    Article  PubMed  CAS  Google Scholar 

  31. Richards AM, Doughty R, Nicholls MG, et al.: Plasma Nterminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001, 37:1781–1787.

    Article  PubMed  CAS  Google Scholar 

  32. Mantymaa P, Vuolteenaho O, Marttila M, Ruskoaho H: Atrial stretch induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expression in vitro. Endocrinology 1993, 133:1470–1473.

    Article  PubMed  CAS  Google Scholar 

  33. Kjaer A, Hildebrandt P, Appel J, Petersen CL: Neurohormones as markers of right- and left-sided cardiac dimensions and function in patients with untreated chronic heart failure. Int J Cardiol 2005, 99:301–306.

    Article  PubMed  Google Scholar 

  34. Talens-Visconti R, Rivera Otero M, Sancho-Tello MJ, et al.: Left ventricular cavity area reflects N-terminal pro-brain natriuretic peptide plasma levels in heart failure. Eur J Echocardiogr 2006, 7:45–52.

    Article  PubMed  Google Scholar 

  35. Groenning BA, Nilsson JC, Sondergaard L, et al.: Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur J Heart Fail 2001, 3:699–708.

    Article  PubMed  CAS  Google Scholar 

  36. Nelson CA, Case C, McCrohon J, Marwick TH: Relationship of extent and nature of dysfunctional myocardium to brain natriuretic peptide in patients with ischemic left ventricular dysfunction. Int J Cardiovasc Imaging 2005, 21:295–300.

    Article  PubMed  Google Scholar 

  37. Lowbeer C, Gustafsson SA, Seeberger A, et al.: Serum cardiac troponin T in patients hospitalized with heart failure is associated with left ventricular hypertrophy and systolic dysfunction. Scand J Clin Lab Invest 2004, 64:667–676.

    Article  PubMed  CAS  Google Scholar 

  38. Iwanaga Y, Nishi I, Furuichi S, et al.: B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006, 47:742–748. LV end-diastolic wall stress is a remarkably robust determinant of cardiac secretion of BNP in patients with diastolic and systolic chronic HF.

    Article  PubMed  CAS  Google Scholar 

  39. Troughton RW, Prior DL, Pereira JJ, et al.: Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 2004, 43:416–422. BNP levels are related to LV diastolic function and to the severity of right ventricular dysfunction and mitral regurgitation in patients with systolic HF.

    Article  PubMed  CAS  Google Scholar 

  40. Yu CM, Sanderson JE, Shum IO, et al.: Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J 1996, 17:1694–1702.

    PubMed  CAS  Google Scholar 

  41. Richards M, Nicholls MG, Espiner EA, et al.: Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 2006, 47:52–60.

    Article  PubMed  CAS  Google Scholar 

  42. Masson S, Latini R, Anand IS, et al.: Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) Data. Clin Chem 2006, 52:1528–1538.

    Article  PubMed  CAS  Google Scholar 

  43. Wong M, Staszewsky L, Latini R, et al.: Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002, 40:970–975.

    Article  PubMed  CAS  Google Scholar 

  44. Goetze JP, Christoffersen C, Perko M, et al.: Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003, 17:1105–1107.

    PubMed  CAS  Google Scholar 

  45. De Lemos JA, Morrow DA, Bentley JH, et al.: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. New Engl J Med 2001, 345:1014–1021.

    Article  PubMed  Google Scholar 

  46. Galvani M, Ottani F, Oltrona L, et al.: N-terminal probrain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 2004, 110:128–134.

    Article  PubMed  CAS  Google Scholar 

  47. Kragelund C, Grønning B, Køber L, et al.: N-terminal probrain natriuretic peptide and long-term mortality in stable coronary heart disease. New Engl J Med 2005, 352:666–675.

    Article  PubMed  CAS  Google Scholar 

  48. Yan RT, White M, Yan AT, et al.: Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol 2005, 96:698–704.

    Article  PubMed  CAS  Google Scholar 

  49. Latini R, Masson S, Wong M, et al.: Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006, 119:7023–30.

    Article  CAS  Google Scholar 

  50. Groenning BA, Nilsson JC, Hildebrandt PR, et al.: Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure. Eur J Heart Fail 2002, 4:635–646.

    Article  PubMed  CAS  Google Scholar 

  51. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000, 101:378–384.

  52. Gackowski A, Isnard R, Golmard JL, et al.: Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J 2004, 25:1788–1796.

    Article  PubMed  CAS  Google Scholar 

  53. Battaglia M, Pewsner D, Juni P, et al.: Accuracy of B-type natriuretic peptide tests to exclude congestive heart failure: systematic review of test accuracy studies. Arch Intern Med 2006, 166:1073–1080.

    Article  PubMed  Google Scholar 

  54. Freitag MH, Vasan RS: Screening for left ventricular systolic dysfunction: the use of B-type natriuretic peptide. Heart Fail Monit 2003, 4:38–44.

    PubMed  Google Scholar 

  55. Richards AM, Troughton R, Lainchbury J, et al.: Guiding and monitoring of heart failure therapy with NT-ProBNP: concepts and clinical studies. J Card Fail 2005, 11:S34–37.

    Article  PubMed  CAS  Google Scholar 

  56. Jourdain P, Funck F, Gueffet P, et al.: Benefit of BNP plasma levels for optimising therapy: the systolic heart failure treatment supported by BNP multicenter randomised trial (STARS-BNP) [abstract]. J Am Coll Cardiol 2005, 45(Suppl 1):3A.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche "Mario Negri,", via Eritrea 62, 20157, Milan, Italy

    Roberto Latini MD

Authors
  1. Roberto Latini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serge Masson PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lidia Staszewsky MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Simona Barlera MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberto Latini MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Latini, R., Masson, S., Staszewsky, L. et al. Neurohormonal modulation in heart failure of ischemic etiology: Correlates with left ventricular remodeling. Curr Heart Fail Rep 3, 157–163 (2006). https://doi.org/10.1007/s11897-006-0016-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-006-0016-8

Keywords

Search

Navigation